Three nonpeptide antagonists, bosentan, macitentan, and ambrisentan, that are either mixed ETA/ETB antagonists or display ETA selectivity, have been approved for clinical use, primarily in pulmonary arterial hypertension. This evidence concerns the gene EDNRB and pulmonary arterial hypertension.